🚀 Product Launch Announcement: Tofaheal 5
(Tofacitinib 5 mg Tablets)
We are pleased to announce the launch of Tofaheal 5, an advanced oral Janus kinase (JAK) inhibitor, designed to meet the therapeutic needs of patients suffering from Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ulcerative Colitis (UC).
With a focus on targeted immunomodulation, Tofaheal 5 delivers powerful, convenient relief for patients with autoimmune and inflammatory conditions, enabling better disease control and improved quality of life.
🔹 About Tofaheal 5
- Active Ingredient: Tofacitinib 5 mg
- Therapeutic Class: Janus Kinase (JAK) Inhibitor
- Indications:
- Treatment of moderate to severe Rheumatoid Arthritis in adults who have had an inadequate response or intolerance to methotrexate.
- Management of active Psoriatic Arthritis in adults.
- Indicated for adults with moderately to severely active Ulcerative Colitis.
🔹 Mechanism of Action
Tofacitinib selectively inhibits Janus kinases (JAK1 and JAK3), interfering with the JAK-STAT signaling pathway responsible for inflammation. This disruption of inflammatory cytokine signaling reduces immune-mediated damage, making Tofaheal 5 an effective oral treatment for chronic autoimmune conditions.
🔹 Key Features and Benefits
✅ Oral Convenience – Eliminates the need for injections, increasing patient comfort and adherence.
✅ Rapid Onset of Action – Clinically proven to reduce symptoms quickly, with noticeable improvements in joint pain and inflammation.
✅ Multi-Disease Use – Effective in treating RA, PsA, and UC with a consistent safety profile.
✅ Backed by Clinical Evidence – Extensive global studies support its efficacy and safety across different autoimmune populations.
✅ Supports Personalized Medicine – Enables flexible treatment planning as monotherapy or in combination.
🏥 Hospitals, Rheumatology & Gastroenterology Clinics
- Suitable for specialty and outpatient care settings.
👨⚕️ Rheumatologists, Gastroenterologists, General Physicians
- Designed to be used after an inadequate response to traditional DMARDs or biologics.
🧍♂️ Patients Living with Autoimmune Disorders
- Offers a non-injectable, potent treatment alternative for improved daily life.
💡 Our Commitment to Innovation in Chronic Disease Care
With the launch of Tofaheal 5, we reaffirm our commitment to bringing trusted, science-driven solutions to the medical community. This breakthrough therapy offers a next-generation approach to managing inflammation, driven by the need for better convenience, efficacy, and quality of life.
Tofaheal 5 — Precision Immunomodulation. Powerful Relief.
📦 Availability
For complete prescribing information, clinical resources, or patient support materials, please contact our medical team or visit Tofaheal 5.
